QuidelOrtho

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com

Portnoy Law Firm is investigating potential securities law violations by QuidelOrtho in connection with its recently reported fourth quarter and full-year 2023 financial results. The focus of the investigation would be on the significant decrease in QuidelOrtho’s GAAP net income for Q4 2023, which fell to $7 million with diluted earnings per share (EPS) of $0.10, down from $30.3 million and $0.45 EPS in the same period of the previous year. The investigation would also examine why the company’s revenue for the quarter, which was $742.6 million, missed forecasts by $44.86 million. Furthermore, the sharp over 38% decline in QuidelOrtho’s stock price in premarket trading on February 14, 2024, following these announcements, would be scrutinized, along with the Board of Directors’ termination of Douglas Bryant, the President and CEO, on February 21, 2024. The aim would be to ascertain if the company and its leadership failed to disclose critical information or made misleading statements regarding the company’s financial status and outlook.